Reading, PA, United States of America

Craig M Potteiger

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 42(Granted Patents)


Location History:

  • Douglassville, PA (US) (2013)
  • Reading, PA (US) (2010 - 2016)

Company Filing History:


Years Active: 2010-2016

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations of Craig M Potteiger

Introduction

Craig M Potteiger is a notable inventor based in Reading, PA (US). He has made significant contributions to the field of pain management through his innovative work. With a total of 8 patents to his name, Potteiger has focused on developing novel therapeutic agents that target specific receptors involved in pain pathways.

Latest Patents

Among his latest patents are the P2X3 receptor antagonists for the treatment of pain. These inventions relate to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain. This includes peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator. His work in this area has the potential to significantly improve the quality of life for individuals suffering from chronic pain conditions.

Career Highlights

Craig M Potteiger is currently associated with Merck Sharp & Dohme Corporation, where he continues to advance his research and development efforts. His career has been marked by a commitment to innovation in the pharmaceutical industry, particularly in the realm of pain management.

Collaborations

Some of his notable coworkers include Christopher S Burgey and Daniel Vincent Paone. Their collaborative efforts contribute to the ongoing research and development of effective pain management solutions.

Conclusion

Craig M Potteiger's work exemplifies the impact of innovative thinking in the field of pain management. His contributions through patents and collaborations highlight the importance of research in developing new therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…